These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 36825202)

  • 21.
    Ke P; Bao X; Liu C; Zhou B; Huo M; Chen Y; Wang X; Wu D; Ma X; Liu D; Chen S
    Transl Cancer Res; 2022 Oct; 11(10):3491-3505. PubMed ID: 36388050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1.
    Quan Y; Li W; Yan R; Cheng J; Xu H; Chen L
    Front Oncol; 2023; 13():1168769. PubMed ID: 37361595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel prognostic signature of cuproptosis-related genes and the prognostic value of FDX1 in gliomas.
    Zhu H; Wan Q; Tan J; Ouyang H; Pan X; Li M; Zhao Y
    Front Genet; 2022; 13():992995. PubMed ID: 36579333
    [No Abstract]   [Full Text] [Related]  

  • 24. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
    Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
    Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
    [No Abstract]   [Full Text] [Related]  

  • 25. A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.
    Wen J; Mao X; Cheng Q; Liu Z; Liu F
    Sci Rep; 2021 Nov; 11(1):22502. PubMed ID: 34795387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint.
    Lu H; Liang J; He X; Ye H; Ruan C; Shao H; Zhang R; Li Y
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
    Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
    Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
    Front Immunol; 2022; 13():933973. PubMed ID: 36045691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated profiling identifies ferredoxin 1 as an immune-related biomarker of malignant phenotype in glioma.
    Xie D; Huang H; Guo Y; Jiang Z; Kuang Y; Huang H; Liu W; Wang L; Xin Z; Wang B; Ren C; Jiang X
    Heliyon; 2024 Mar; 10(5):e26976. PubMed ID: 38463788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer.
    Zhou X; Wang Y; Zheng J; Wang S; Liu C; Yao X; Ren Y; Wang X
    Front Genet; 2022; 13():990301. PubMed ID: 36276934
    [No Abstract]   [Full Text] [Related]  

  • 32. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic and immunological role of MCM3 in pan-cancer and validation of prognosis in a clinical lower-grade glioma cohort.
    Huang QR; Jiang Q; Tan JY; Nong RB; Yan J; Yang XW; Mo LG; Ling GY; Deng T; Gong YZ
    Front Pharmacol; 2024; 15():1390615. PubMed ID: 38698811
    [No Abstract]   [Full Text] [Related]  

  • 34. Novel Cuproptosis-Related Gene Signature for Precise Identification of High-Risk Populations in Low-Grade Gliomas.
    Chen P; Han H; Wang X; Wang B; Wang Z
    Mediators Inflamm; 2023; 2023():6232620. PubMed ID: 36814682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma.
    Qiu H; Tian W; He Y; Li J; He C; Li Y; Liu N; Li J
    Front Oncol; 2021; 11():654350. PubMed ID: 33954112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of
    Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
    Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of cuproptosis-related subtypes and the development of a prognostic model in glioma.
    Wu Z; Li W; Zhu H; Li X; Zhou Y; Chen Q; Huang H; Zhang W; Jiang X; Ren C
    Front Genet; 2023; 14():1124439. PubMed ID: 36936439
    [No Abstract]   [Full Text] [Related]  

  • 39. Pan-Cancer Analysis of the Prognostic and Immunological Role of SMG5: A Biomarker for Cancers.
    Yang L; Wei J; Ma X; Cheng R; Zhang H; Jin T
    Oncology; 2024; 102(2):168-182. PubMed ID: 37699361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
    Yang W; Liu Z; Liu T
    Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.